TNIP2 Antibody

What is TNIP2 and what cellular functions does it perform?

TNIP2, also known as ABIN2, FLIP1, or KLIP, functions as a key regulatory protein in the NF-κB signaling pathway. This 49 kDa protein has dual regulatory capabilities, acting as both an inhibitor and an activator of NF-κB-dependent transcription under different conditions . TNIP2 was initially identified as a binding partner of A20 (TNFAIP3), a negative regulator of NF-κB signaling .

The protein exhibits complex functionality across multiple cellular processes:

• It inhibits NF-κB activation by blocking the interaction between RIPK1 and NEMO/IKBKG

• It functions as a transcriptional coactivator when translocated to the nucleus

• It interacts with the ESCRT-I complex via the TSG101 subunit, potentially linking it to processes including vacuolar protein sorting and HIV-1 viral budding

• It associates with specific mRNAs involved in transcription factor binding and regulatory activities

• It forms ternary complexes with NFKB1 (p105) and MAP3K8 (Tpl2), suggesting roles in multiple signaling cascades

TNIP2 is predominantly localized in both the cytoplasm and nucleus, with cellular distribution potentially regulating its diverse functions .

What epitopes of TNIP2 are commonly targeted by research antibodies?

Commercial antibodies against TNIP2 target various regions of the protein, enabling researchers to investigate different functional domains:

• N-terminal region (N-Term): Antibodies targeting the N-terminus recognize sequences that mediate interaction with NFKB1 (p105)

• AA 20-200: This region contains domains critical for protein-protein interactions and regulatory functions

• AA 61-110: Mid-region antibodies target a conserved functional domain

• AA 85-180: Covers a central functional domain of the protein

• AA 170-413: Targets the C-terminal half which can translocate to the nucleus and activate gene expression

• AA 240-429: The C-terminal region contains sequences involved in transcriptional coactivator functions

Selecting the appropriate epitope-specific antibody is critical depending on whether researchers are studying protein interactions, subcellular localization, or functional activities of TNIP2 .

What are optimal conditions for Western blot detection of TNIP2?

Successful Western blot detection of TNIP2 requires careful optimization of experimental conditions:

Sample preparation:

• Cell types known to express TNIP2 include HepG2 cells and mouse liver tissue

• Typical lysis buffers containing protease inhibitors are recommended to prevent degradation

Antibody dilutions and incubation:

• Primary antibody dilutions typically range from 1:500 to 1:4000, but optimal dilution is antibody-dependent

• For example, the Proteintech antibody (15459-1-AP) is recommended at 1:1000-1:4000 dilution

• Overnight incubation at 4°C often yields optimal results

Detection considerations:

• Expected molecular weight is approximately 49 kDa (calculated), but TNIP2 typically appears at approximately 50 kDa in gel electrophoresis

• Potential post-translational modifications may cause mobility shifts

• Both reducing and non-reducing conditions may be tested to optimize detection

Controls:

• Positive controls: HepG2 cells or mouse liver tissue extracts

• Negative controls: Samples known not to express TNIP2 or siRNA knockdown samples

Researchers should validate each new TNIP2 antibody lot with appropriate positive and negative controls before proceeding with experimental samples .

How should samples be prepared for immunohistochemistry with TNIP2 antibodies?

Optimal immunohistochemistry (IHC) protocols for TNIP2 detection require specific sample preparation techniques:

Fixation and sectioning:

• Standard formalin fixation and paraffin embedding (FFPE) techniques are typically suitable

• Section thickness of 4-6 μm is recommended for optimal antibody penetration

Antigen retrieval methods:

• Heat-induced epitope retrieval (HIER) is essential for most TNIP2 antibodies

• Recommended buffers include:

  • TE buffer at pH 9.0 (primary recommendation for antibody 15459-1-AP)

  • Citrate buffer at pH 6.0 (alternative method)

• Optimization of retrieval time (typically 10-20 minutes) may be necessary

Antibody dilutions:

• Working dilutions vary significantly between antibodies:

  • Proteintech antibody (15459-1-AP): 1:20-1:200 for IHC applications

  • Other antibodies may require different dilutions as specified by manufacturers

Detection systems:

• For low abundance targets, amplification systems like HRP-polymer or TSA may improve sensitivity

• Both DAB and fluorescent detection methods have been validated for TNIP2

Positive control tissues:

• Human liver tissue has been validated as a positive control for TNIP2 IHC

• Mouse pancreas also shows detectable TNIP2 expression

Researchers should perform titration experiments with each new antibody lot to determine optimal conditions for their specific tissue samples .

What controls are essential when validating TNIP2 antibody specificity?

Rigorous validation of TNIP2 antibody specificity requires multiple complementary approaches:

Positive controls:

• Cell lines with known TNIP2 expression (e.g., HepG2)

• Tissue samples with confirmed TNIP2 expression (e.g., human liver, mouse pancreas)

• Overexpression systems using TNIP2 expression vectors

Negative controls:

• TNIP2 knockout cells or tissues (generated via CRISPR-Cas9 or similar technologies)

• siRNA/shRNA knockdown samples showing reduced signal intensity

• Secondary antibody-only controls to assess background

• Isotype controls to evaluate non-specific binding

Peptide competition assays:

• Pre-incubation of the antibody with excess immunizing peptide should abolish specific signals

• This approach is particularly valuable for polyclonal antibodies

Cross-validation methods:

• Comparison of results using multiple antibodies targeting different TNIP2 epitopes

• Correlation with mRNA expression data from RT-PCR or RNA-seq

• Mass spectrometry validation of immunoprecipitated proteins

Recombinant protein standards:

• Using purified recombinant TNIP2 protein as a standard for Western blot

• Testing antibody against truncated TNIP2 constructs to confirm epitope specificity

Comprehensive validation using multiple approaches significantly improves confidence in experimental results and is essential for publication-quality research .

How can TNIP2 antibodies be used to investigate NF-κB signaling pathways?

TNIP2 antibodies enable sophisticated analysis of NF-κB signaling through multiple experimental approaches:

Co-immunoprecipitation (Co-IP) studies:

• TNIP2 antibodies can be used to pull down protein complexes to study interactions with:

  • NF-κB components (NFKB1/p105, RELA, REL, RELB)

  • A20/TNFAIP3 (a negative regulator of NF-κB)

  • ESCRT-I complex components, particularly TSG101

  • MAP3K8/Tpl2 for investigating ternary complex formation

• Reciprocal IPs with antibodies against interaction partners can confirm associations

Chromatin immunoprecipitation (ChIP):

• When TNIP2 translocates to the nucleus, ChIP using TNIP2 antibodies can identify genomic binding sites

• Sequential ChIP (ChIP-reChIP) can determine co-occupancy with NF-κB transcription factors

Subcellular fractionation and localization:

• TNIP2 antibodies can track nuclear translocation following various stimuli

• Immunofluorescence microscopy with TNIP2 antibodies can visualize dynamic localization changes

• Comparison of cytoplasmic versus nuclear TNIP2 levels in response to pathway stimulation or inhibition

Proximity ligation assays (PLA):

• PLA combining TNIP2 antibodies with antibodies against NF-κB components can visualize protein-protein interactions in situ

• This technique enables detection of transient interactions within intact cells

Phosphorylation-specific analysis:

• Combined use of TNIP2 antibodies with phospho-specific antibodies can track activation states

• IP-western approach: TNIP2 IP followed by phospho-specific western blot detection

Researchers should carefully select antibodies with appropriate epitope recognition to avoid disrupting the protein-protein interactions being studied .

What techniques can be used to study TNIP2's RNA-binding properties?

Research has revealed unexpected RNA-binding capabilities of TNIP2, which can be investigated using several specialized techniques:

RNA immunoprecipitation (RIP):

• TNIP2 antibodies can precipitate protein-RNA complexes to identify associated RNA molecules

• Critical controls include RNase treatment, which should abolish RNA-dependent protein interactions

• Known TNIP2-associated proteins like KHDRBS1 are lost upon RNA depletion, confirming RNA-dependent interactions

Cross-linking immunoprecipitation (CLIP) and variants:

• CLIP-seq combines UV cross-linking with TNIP2 immunoprecipitation and RNA sequencing

• This approach can identify direct RNA-protein interaction sites with nucleotide resolution

• Variants like PAR-CLIP, iCLIP, or eCLIP may offer improved resolution of binding sites

RNA-protein pull-down assays:

• Synthetic RNA transcripts corresponding to identified TNIP2-binding RNAs can be used as bait

• Western blotting with TNIP2 antibodies confirms binding to specific RNA sequences

• Mutational analysis of RNA sequences can identify critical binding motifs

RNA-Seq after TNIP2 IP:

• RNA sequencing of TNIP2-associated RNA has revealed enrichment for transcripts involved in:

  • Transcription factor binding

  • Transcription factor cofactor activity

  • Transcription regulator activity

• This approach provides comprehensive identification of the TNIP2 RNA interactome

In vitro binding assays:

• Recombinant TNIP2 protein can be tested for direct RNA binding using electrophoretic mobility shift assays (EMSA)

• Surface plasmon resonance (SPR) can determine binding kinetics and affinity

These techniques can help elucidate the emerging role of TNIP2 as an RNA-binding protein that may regulate post-transcriptional processes in addition to its established role in NF-κB signaling .

How can post-translational modifications of TNIP2 be detected?

Investigation of TNIP2 post-translational modifications (PTMs) requires specialized experimental approaches:

Phosphorylation analysis:

• Immunoprecipitation with TNIP2 antibodies followed by:

  • Phospho-specific western blotting

  • Mass spectrometry analysis to identify specific phosphorylation sites

• Comparison of TNIP2 mobility shifts before and after phosphatase treatment

• Use of phosphorylation-specific antibodies if available for known modification sites

Ubiquitination detection:

• TNIP2 contains a ubiquitin-binding domain (UBD)

• Detection approaches include:

  • IP under denaturing conditions to preserve ubiquitin modifications

  • Western blotting with anti-ubiquitin antibodies

  • Tandem ubiquitin binding entity (TUBE) pulldowns followed by TNIP2 detection

SUMOylation analysis:

• IP with TNIP2 antibodies followed by anti-SUMO western blotting

• Comparison of band patterns in the presence of SUMO protease inhibitors

• Analysis of putative SUMO consensus sites by site-directed mutagenesis

Mass spectrometry-based PTM profiling:

• IP of TNIP2 followed by tryptic digestion and LC-MS/MS analysis

• Data analysis platforms like MaxQuant or Proteome Discoverer can identify multiple PTM types

• Targeted multiple reaction monitoring (MRM) can quantify specific modifications

Functional validation of PTMs:

• Site-directed mutagenesis of modified residues to assess functional consequences

• Phosphomimetic mutations (e.g., Ser→Asp) compared with non-phosphorylatable mutations (e.g., Ser→Ala)

• Correlation of PTM status with functional outcomes like protein interactions or subcellular localization

Understanding TNIP2's post-translational modification pattern is critical for deciphering its regulatory mechanisms in different cellular contexts and signaling states .

Why might TNIP2 antibodies show variable molecular weights in Western blot?

TNIP2 has a calculated molecular weight of 49 kDa but is often observed at approximately 50 kDa in Western blots . Several factors may explain this discrepancy and other variations in observed molecular weight:

Post-translational modifications:

• Phosphorylation, ubiquitination, or SUMOylation can increase apparent molecular weight

• Multiple modified forms may appear as multiple bands or smears

• These modifications may vary based on cell type or stimulation conditions

Protein isoforms:

• Alternative splicing could generate TNIP2 variants with different molecular weights

• Some antibodies may recognize all isoforms while others may be isoform-specific

Antibody specificity issues:

• Cross-reactivity with related proteins (e.g., other TNIP family members)

• Non-specific binding to similarly sized proteins

• Resolution by using multiple antibodies targeting different TNIP2 regions

Technical considerations:

• Gel concentration affects protein migration (higher percentage gels may improve resolution)

• Buffer systems (Tris-glycine vs. Tris-tricine) can influence apparent molecular weight

• Comparison with molecular weight standards can vary between gel systems

Sample preparation effects:

• Incomplete denaturation may result in aberrant migration

• Reducing vs. non-reducing conditions can affect mobility

• Heat-induced aggregation or degradation may generate additional bands

When encountering unexpected band patterns, researchers should validate findings using multiple antibodies targeting different epitopes and correlate with additional techniques such as mass spectrometry or knockdown/knockout controls .

How can non-specific binding be minimized when using TNIP2 antibodies?

Non-specific binding is a common challenge with antibody-based techniques. Several strategies can minimize this issue when working with TNIP2 antibodies:

Western blot optimization:

• Blocking optimization:

  • Test different blocking agents (BSA, non-fat milk, commercial blockers)

  • Typically 3-5% blocking solution concentration is effective

  • Extended blocking times (1-2 hours at room temperature or overnight at 4°C)

• Antibody dilution optimization:

  • Titrate antibodies to determine optimal concentration (typically 1:1000-1:4000 for TNIP2)

  • Prepare antibodies in fresh blocking solution

  • Consider longer incubation at lower concentration versus shorter at higher concentration

• Washing stringency:

  • Increase number of washes (minimum 3-5 washes of 5-10 minutes each)

  • Add low concentrations of detergent (0.1-0.3% Tween-20) to wash buffers

  • Consider high-salt washes (up to 500 mM NaCl) for particularly problematic antibodies

Immunohistochemistry/Immunofluorescence optimization:

• Tissue preparation:

  • Optimize fixation time to preserve epitopes while maintaining tissue morphology

  • Test multiple antigen retrieval methods (TE buffer pH 9.0 and citrate buffer pH 6.0 recommended for TNIP2)

• Background reduction:

  • Include serum from the secondary antibody host species in blocking solution

  • Pre-adsorb secondary antibodies if tissue-specific background persists

  • Use avidin/biotin blocking for tissues with endogenous biotin

• Controls:

  • Include secondary-only controls to assess background

  • Use isotype control antibodies at matched concentration

Immunoprecipitation optimization:

• Pre-clear lysates with protein A/G beads before adding antibody

• Use crosslinking approaches to attach antibody covalently to beads

• Optimize wash stringency to maintain specific interactions while reducing background

• For quantitative IP experiments, consider antibody titration to determine optimal amounts

By systematically optimizing these parameters, researchers can significantly improve signal-to-noise ratio when working with TNIP2 antibodies .

What approaches can resolve contradictory results between different TNIP2 antibodies?

When different TNIP2 antibodies yield conflicting results, systematic troubleshooting approaches can help resolve discrepancies:

Epitope mapping and accessibility:

• Different antibodies recognize distinct TNIP2 epitopes that may be differentially accessible:

  • N-terminal antibodies target regions involved in NFKB1 interactions

  • Central region antibodies may recognize domains involved in ESCRT-I binding

  • C-terminal antibodies detect regions involved in nuclear localization

• Protein conformation, complex formation, or post-translational modifications may mask specific epitopes

• Solution: Map exactly which regions each antibody recognizes and interpret results in light of known functional domains

Validation using genetic approaches:

• Generate TNIP2 knockout/knockdown samples:

  • CRISPR-Cas9 knockout cell lines

  • siRNA/shRNA knockdown experiments

  • Test all antibodies against these controls to assess specificity

• Complementary overexpression studies:

  • Express tagged TNIP2 constructs and detect with both anti-tag and anti-TNIP2 antibodies

  • Test truncated TNIP2 constructs to confirm epitope recognition

Cross-technique validation:

• Compare results across multiple techniques:

  • Western blot

  • Immunoprecipitation

  • Immunofluorescence

  • Flow cytometry

• Discrepancies between techniques may reveal context-dependent epitope masking

Quantitative comparative analysis:

• Direct comparison of multiple antibodies:

  • Side-by-side testing under identical conditions

  • Titration experiments to determine optimal working concentration for each antibody

  • Assessment of signal-to-noise ratio for each antibody

Third-party validation:

• Mass spectrometry analysis of immunoprecipitated material

• RNA-level validation using RT-PCR or RNA-seq

• Literature-based evidence reconciliation by examining experimental conditions

When presenting results obtained with TNIP2 antibodies, researchers should clearly indicate which antibody was used, its target epitope, and include appropriate validation data to support their findings .

How can TNIP2 antibodies be utilized in therapeutic disease research?

TNIP2's involvement in NF-κB signaling makes it relevant to numerous pathological conditions where this pathway is dysregulated:

Inflammatory disorders:

• TNIP2 antibodies can help assess protein levels in inflammatory disease models

• Tissue microarray analysis of patient samples may reveal altered TNIP2 expression

• Correlation of TNIP2 levels with disease severity or treatment response

Cancer research applications:

• Analysis of TNIP2 expression across cancer types and stages

• Investigation of nuclear versus cytoplasmic localization in tumor versus normal tissue

• Correlation with known NF-κB activation signatures

Neurodegenerative disease research:

• Assessment of TNIP2 levels in models of neuroinflammation

• Investigation of TNIP2-RNA interactions relevant to neurodegeneration

• Evaluation of TNIP2 as a potential biomarker or therapeutic target

Viral pathogenesis studies:

• TNIP2 interacts with the ESCRT-I complex via TSG101, which is essential for HIV-1 budding

• TNIP2 antibodies can help elucidate mechanisms of viral manipulation of host signaling

• Investigation of TNIP2 modulation during viral infection cycles

Drug discovery applications:

• Target engagement studies for compounds designed to modulate TNIP2 function

• Phenotypic screening approaches using TNIP2 localization or expression as readouts

• Biomarker development for targeted therapies affecting NF-κB pathways

As research into TNIP2's diverse functions continues to expand, antibodies against this protein will remain essential tools for understanding its role in disease pathogenesis and therapeutic modulation .

What novel techniques are emerging for TNIP2 protein-protein interaction studies?

Advanced technologies are enhancing our ability to study TNIP2's complex interactome:

Proximity labeling approaches:

• BioID or TurboID fusion with TNIP2 enables proximity-dependent biotinylation of interacting proteins

• APEX2-TNIP2 fusions allow electron microscopy-compatible proximity labeling

• These techniques can identify transient or weak interactions missed by traditional co-immunoprecipitation

Live-cell interaction monitoring:

• FRET/BRET sensors incorporating TNIP2 allow real-time monitoring of protein interactions

• Split luciferase complementation assays can detect TNIP2 interactions with suspected partners

• Fluorescence correlation spectroscopy (FCS) can characterize interaction dynamics

Proteomics advancements:

• Crosslinking mass spectrometry (XL-MS) can map interaction interfaces between TNIP2 and partners

• Hydrogen-deuterium exchange mass spectrometry (HDX-MS) reveals conformational changes upon binding

• Thermal proximity coaggregation (TPCA) assesses interactions under near-native conditions

High-resolution imaging:

• Super-resolution microscopy using TNIP2 antibodies provides nanoscale localization information

• Expansion microscopy can physically enlarge samples for improved resolution of complex formation

• Correlative light and electron microscopy (CLEM) links TNIP2 localization to ultrastructural context

Computational approaches:

• Molecular dynamics simulations can predict interaction interfaces

• Machine learning algorithms can integrate multiple data types to predict novel interactions

• Network analysis of proteomic data can identify hub functions within signaling networks

These emerging technologies complement traditional antibody-based approaches and are expanding our understanding of TNIP2's diverse roles as a hub protein in multiple cellular processes .